Home › Cancro metastatico › Florida › Tampa
Studi clinici su Cancro metastatico a Tampa, FL
29 studi su Cancro metastatico cercano partecipanti presso sedi a Tampa e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
In reclutamentoFase 1/2
- Avenzo Therapeutics Recruiting Site, Tampa
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
In reclutamentoFase 1
- Moffitt Cancer Center, Tampa
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
In reclutamentoFase 1
- ALX Center 7, Tampa
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
In reclutamentoFase 2/3
- Moffitt Cancer Center, Tampa
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
In reclutamentoFase 1
- Moffitt Cancer Center, Tampa
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
In reclutamentoFase 2
- Moffitt Cancer Center, Tampa
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
In reclutamentoFase 3
- Florida Cancer Specialists, Tampa
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
In reclutamentoFase 1
- Moffitt, Tampa
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
In reclutamentoFase 3
- Moffitt Cancer Center, Tampa
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
In reclutamentoFase 3
- Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center, Tampa
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
In reclutamentoFase 1/2
- Moffitt Cancer Center and Research Institute, Tampa
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
In reclutamentoFase 1/2
- Moffitt Cancer Center, Tampa
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
In reclutamentoFase 1/2
- Avenzo Therapeutics Recruiting Site, Tampa
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
In reclutamentoFase 1
- Moffitt Cancer Center, Tampa
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
In reclutamentoFase 3
- Research Site, Tampa
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
In reclutamentoFase 1
- Investigative Site #128, Tampa
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
In reclutamentoFase 1
- Moffitt Cancer Center, Tampa
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
In reclutamentoFase 3
- Moffitt Cancer Center, Tampa
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
In reclutamentoFase 1
- Exelixis Clinical Site #8, Tampa
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
In reclutamentoFase 3
- Moffitt Cancer Center, Tampa
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
In reclutamentoFase 2
- James A. Haley Veterans Administration Hospital, Tampa
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
In reclutamentoFase 1
- Moffitt Cancer Center, Tampa
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
In reclutamentoFase 1
- Lee Moffitt Cancer Center, Tampa
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
In reclutamentoFase 1
- Moffitt Cancer Center, Tampa
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
In reclutamentoFase 1/2
- Moffitt Cancer Center, Tampa
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
In reclutamentoFase 2/3
- Moffitt Cancer Center, Tampa
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
In reclutamentoFase 3
- Moffitt Cancer Center, Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Tampa
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
In reclutamentoFase 1
- H. Lee Moffitt Cancer Center and Research Institute, Tampa
Studi su Cancro metastatico in altre città
- Houston, TX104 studi
- New York City, NY93 studi
- Nashville, TN70 studi
- Boston, MA63 studi
- Los Angeles, CA57 studi
- St. Louis, MO54 studi
- Arlington, VA53 studi
- Philadelphia, PA46 studi
- Chicago, IL45 studi
- San Antonio, TX44 studi
- Washington, DC43 studi
- Dallas, TX42 studi
Altri studi a Tampa
- Cancro del polmone non a piccole cellule51 studi
- Cancro al seno43 studi
- Cancro (tutti i tipi)39 studi
- Cancro colorettale34 studi
- Leucemia mieloide acuta29 studi
- Cancro ai polmoni29 studi
- Cancro pancreatico26 studi
- Cancro ovarico21 studi
- Melanoma19 studi
- Sindromi mielodisplastiche19 studi
- Cancro alla prostata18 studi
- Insufficienza cardiaca18 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.